Table 3.
Percent changes in serum 25(OH)D and markers of inflammation and immunity from baseline at 12 wks and 1 yr among all subjects1
| Vitamin D | Placebo | |||
|---|---|---|---|---|
| 12 wks | 1 yr | 12 wks | 1 yr | |
| 25(OH)D (%) | 77 ± 1222, 3 | 73 ± 114 | −18 ± 19 | −5 ± 19 |
| TNF (%) | −2.8 (−10.6, 2.1) | 1.1 (−5.6, 16.0)– | −0.9 (−3.2, 3.2) | 0.9 (−6.0, 7.8) |
| IL-6 (%) | 1.2 (−2.6, 13.2) | 2.2 (−10.1, 10.4) | 1.3 (−2.6, 7.4) | 1.3 (−7.0, 3.6) |
| NGAL (%) | −6.7 ± 15.92 | 2.5 ± 36.9 | −0.1 ± 16.8 | −4.3 ± 24.5 |
| MCP-1 (%) | −6.2 ± 13.32, 3 | −3.0 ± 14.5 | 6.5 ± 14.22 | 2.5 ± 13.2 |
| IP-10 (%) | 1.6 (−4.2, 12.3) | −1.3 (−15.9, 28.0) | 1.5 (−5.2, 10.5) | 3.3 (–8.9, 13.3) |
| LL-37 (%) | 1.9 (−3.9, 15.0) | ----- | 2.01 (−3.1, 11.7) | ----- |
1
Value reported as median (IQR) or mean (±SD). Abbreviations: 25(OH)D, 25-hydroxyvitamin D; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; NGAL, neutrophil gelatinase-associated lipocalin; MCP-1, monocyte chemoattractant protein-1; IP-10, interferon gamma-induced protein-10; LL-37, cathelicidin.
2
P < 0.10 for change from baseline (Wilcoxon signed rank test or paired t-test)
3
P < 0.05 for difference from placebo (Wilcoxon rank sum test or two-group t-test)